Related Experiment Video
Updated: Nov 3, 2025
08:59
Utilizing the Precision-Cut Lung Slice to Study the Contractile Regulation of Airway and Intrapulmonary Arterial Smooth Muscle
Published on: May 5, 2022
3.8K
Targeting Airway Smooth Muscle Hypertrophy in Asthma: An Approach Whose Time Has Come
Anne Chetty1, Heber C Nielsen1
1Tufts Medical Center, Tufts University, Boston, MA, USA.
Journal of Asthma and Allergy
|June 3, 2021
Summary
Airway smooth muscle (ASM) cell dysfunction drives asthma severity. This review explores factors causing ASM hypertrophy and proliferation, highlighting targeted therapies to reduce ASM mass and improve asthma control.
Area of Science:
- Pulmonary Medicine
- Cell Biology
- Respiratory Disease Research
Background:
- Airway smooth muscle (ASM) cell dysfunction is central to obstructive pulmonary diseases like asthma.
- Environmental factors trigger ASM cell hypertrophy, proliferation, and migration, contributing to difficult-to-control asthma.
- ASM cells exhibit phenotypic plasticity, responding to extracellular matrix and soluble mediators.
Purpose of the Study:
- To review factors driving ASM hypertrophy and proliferation in asthma.
- To discuss current and potential therapeutic strategies targeting ASM hypertrophy.
- To identify translational research opportunities for improved asthma management.
Main Methods:
- Literature review focusing on cytokines, growth factors, and ion transporters.
- Analysis of mechanisms underlying ASM cell hypertrophy and proliferation.
- Evaluation of therapeutic targets for reducing ASM mass.
Main Results:
- Cytokines, growth factors, and ion transporters are key mediators of ASM hypertrophy and proliferation.
- ASM remodeling contributes significantly to asthma pathophysiology.
- Targeting ASM hypertrophy offers a promising avenue for asthma therapy.
Conclusions:
- Understanding the factors controlling ASM cell behavior is crucial for asthma treatment.
- Therapeutic strategies aimed at reducing ASM mass show potential for clinical translation.
- Further research into targeted ASM therapies could significantly improve asthma outcomes.
Related Concept Videos
01:20Asthma: Pathogenesis and Management
898
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
898
01:26Asthma-II: Pathophysiology and Classification
3.5K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.5K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.4K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.4K
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
1.4K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.4K
01:24Antiasthma Drugs: Methylxanthines
1.3K
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
1.3K
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.5K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.5K